Paterson Group
Designing and synthesising chelators and targeted radiopharmaceuticals for the diagnosis and treatment of disease
The Paterson Group, led by Group Leader Associate Professor Brett Paterson, is designing and synthesising chelators and targeted radiopharmaceuticals for the diagnosis and treatment of disease.
The targeted delivery of radiation in precision nuclear medicine can be achieved with stable incorporation of certain radioactive isotopes (radionuclides) into biologically active molecules. The resulting ‘radiopharmaceuticals’ can then be used as diagnostic and therapeutic agents.For the radiation from radionuclides to be truly effective in nuclear medicine, there must be a deep understanding of the fundamental chemistry, physics and biology of the radionuclides and the radiopharmaceutical delivery system. Our research connects the fields of chemistry, radiochemistry, biology and imaging science to design, synthesise and evaluate new radiopharmaceuticals.
Research Areas
- Inorganic chemistry
- Organic synthesis
- Radiochemistry
- Bioconjugation
- Molecular imaging
- Radiobiology
- Radionuclide production
Research Approach
With access to the state-of-the-art equipment and facilities within the Centre for Advanced Imaging and AIBN, we are tackling the challenge of understanding and utilising radiation and radionuclides for radiopharmaceutical development and translation. We focus on the synthesis of novel chelators, small molecules and peptides, the utilisation of effective bioconjugation approaches and the use of established and innovative radionuclides for molecular imaging, radiotherapeutic and radiobiological evaluation.
Research Highlights
Funding
Since 2019
- Understanding production and application of alpha emitting radionuclides
(2023–2025) ARC Linkage Projects - ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals
(2023–2028) ARC Industrial Transformation Research Hubs
Publications
Click here to view Paterson group publications
